Great AMR-focused podcast series on BBC Discovery!
Dear All, The BBC’s Roland Pease has put together a 3-part podcast series on AMR! Each episode is about 30 minutes, perfect for bite-sized listening.
6 April 2026
No Comments
John Rex
Antimicrobial Effectiveness: The strategic economic value of antibiotics
Dear All (and with thanks to Lucy Naga for being the lead author on this economic-focused newsletter), Antimicrobials are the quiet safety net of modern
27 March 2026
No Comments
WHO: New TPPs for antibacterial agents
Dear All, You may recall that in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A description of the desired attributes
23 March 2026
No Comments
EMA: “Regulatory sandboxes” to explore approval pathways
Dear All, No, EMA has not decided to set up shop on the beach! Rather, the point of this newsletter is that I heard a fascinating
12 March 2026
No Comments
CARB-X seeks new Chief of R&D (fully remote, worldwide)
Dear All, A very senior and globally significant leadership opportunity has appeared: CARB-X is seeking to recruit a new Chief of Research & Development! Given CARB-X’s role as
9 March 2026
No Comments
FDA: One pivotal trial (+ confirmatory evidence) is default expectation for approval
Dear All (a wonkish guide to something you may have thought was obvious AND with thanks to Aaron Dane for co-authoring this newsletter), In a
1 March 2026
No Comments
Workshop on diagnostics: Can we drive use by making value visible?
Dear All (and with thanks to Robert Skov for co-authoring this newsletter AND with a wonkish alert for this complicated topic for which a compelling
17 February 2026
No Comments
PASTEUR (v2.0) reintroduced in the US Congress!
Dear All, I’m delighted to be able to say that PASTEUR 2026 was (re)introduced into the US Congress this week! It’s an improved version relative
12 February 2026
No Comments
The global funding pipeline, 2017-2023: A review
Dear All, In a thoughtful companion to WHO’s preclinical and clinical pipeline reviews, we now have an instructive analysis of the global funding pipeline for
7 February 2026
No Comments
FDA RFPs: Susceptibility breakpoints and external controls for invasive fungal infections
Dear All, I just today learned that FDA has posted two antimicrobial resistance-related (AMR-related) FY 2026 funding opportunities. The titles for the RFPs are very
5 February 2026
No Comments